drugset / Trial / NCT07000305

A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer

NCT07000305

Phase 2 Not yet recruiting 42 enrolled Tao Zhang
NaSingle-groupOpen-labelTreatment

Summary

A study of Cetuximabβ combined with Envolimab and mFOLFOX6 in Subjects with Advanced Colorectal Cancer

Timeline

Start
2025-05-20
Primary completion
2027-05-20
Completion
2028-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab β Monoclonal antibody 500 mg/m2 Intravenous
Subject Envolimab Unknown 200 mg Subcutaneous

Indications